A phase 1 study of MM-141, a novel tetravalent monoclonal antibody targeting IGF-1R and ErbB3, in relapsed or refractory solid tumors. (December 2016) - Isakoff, S.; Bahleda, R.; Saleh, M.; Bordoni, R.; Shields, A.; Dauer, J.; Curley, M.; Baum, J.; McClure, T.; Louis, C.U.; Soria, J.C.